影像科学与光化学 ›› 2022, Vol. 40 ›› Issue (5): 1164-1168.DOI: 10.7517/issn.1674-0475.220406

• 综述与论文 • 上一篇    下一篇

利伐沙班联合尿激酶对LEDVT的治疗效果及超声参数的影响

王佳1, 李晓天1, 宋昊2   

  1. 1. 郑州大学药学院, 河南 郑州 450000;
    2. 河南省人民医院药学部静配中心, 河南 郑州 450000
  • 收稿日期:2022-04-26 发布日期:2022-09-13
  • 通讯作者: 李晓天

Therapeutic Effect of Rivaroxaban Combined with Urokinase on LEDVT Treatment and Its Effects on Ultrasound Parameters

WANG Jia1, LI Xiaotian1, SONG Hao2   

  1. 1. School of Pharmacy, Zhengzhou University, Zhengzhou 450000, Henan, P. R. China;
    2. Jingpei Center, Pharmacy Department, Henan Provincial People's Hospital, Zhengzhou 450000, Henan, P. R. China
  • Received:2022-04-26 Published:2022-09-13

摘要: 本文分析利伐沙班联合尿激酶对下肢深静脉血栓(LEDVT)患者溶栓治疗的效果及超声评估。通过选取100例LEDVT患者为研究对象,按照随机数字表法分为对照组(50例)和研究组(50例)。对照组采用尿激酶治疗,研究组采用利伐沙班联合尿激酶治疗,检测对比两组炎症因子、凝血功能指标、超声参数水平及临床疗效。治疗后两组白细胞介素-18(IL-18)、C反应蛋白(CRP)、白细胞介素-6(IL-6)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)、凝血酶时间(TT)、凝血原酶时间(PT)、收缩期峰值流速(PSV)、舒张末期流速(EDV)水平降低,且研究组低于对照组;治疗后两组阻力指数(RI)水平升高,且研究组高于对照组(P<0.05)。与研究组治疗无效患者相比,治疗有效患者PSV、EDV水平较低,RI水平较高(P<0.05)。研究组治疗有效率明显高于对照组(P<0.05)。综上可知,下肢深静脉血栓通过利伐沙班、尿激酶联合治疗后炎症因子水平下降、凝血功能改善,且联合治疗后超声参数变化明显,提示超声可用于下肢深静脉血栓患者溶栓效果的评估。

关键词: 下肢深静脉血栓, 尿激酶, 利伐沙班, 彩色多普勒超声

Abstract: This paper analyzed the therapeutic effect and ultrasound assessment of rivaroxaban combined with urokinase for thrombolysis in patients with lower extremity deep venous thrombosis (LEDVT). Selected 100 patients with LEDVT as research subjects, according to the method of random number table they were divided into the control group with 50 cases and the study group with 50 cases. The control group was treated with urokinase, and the study group was treated with rivaroxaban + urokinase to detect and compare the inflammatory cytokines, coagulation function indicators, ultrasound parameters level and clinical efficacy of the two groups. After treatment, The levels of Interleukin-18 (IL-18), C reactive protein (CRP), interleukin-6 (IL-6), activated partial thromboplastin time (APTT), fibrinogen (FIB), thrombin time (TT), prothrombin time (PT), peak systolic velocity (PSV) and end diastolic velocity (EDV) were reduced, and the study group was lower than the control group. The RI levels of the two groups were increased after treatment, in addition, the study group was higher than the control group (P<0.05). Compared with the ineffective patients in research group, the effective patients have lower levels of PSV, EDV and higher level of RI were lower (P<0.05). The treatment response rate in research group was significantly higher than the control group (P<0.05). In conclusion, it could be seen that the inflammatory factors decreased and coagulation function improved for deep vein thrombosis after rivaroxaban and urokinase combined treatment, and the ultrasound parameters changed significantly after combined treatment. All these suggested that ultrasound could be used to evaluate thrombolysis effect in patients with LEDVT.

Key words: lower extremity deep venous thrombosis, urokinase, rivaroxaban, color doppler ultrasound